U.S. FDA declines to approve Sesen Bio's bladder cancer treatment – Reuters

U.S. FDA declines to approve Sesen Bio’s bladder cancer treatment – Reuters

The U.S. Food and Drug Administration has declined to approve Sesen Bio Inc’s (SESN.O) lead therapy candidate for a type of bladder cancer, the drug developer said on Friday.

Read More…